Advances in Targeting HER3 as an Anticancer Therapy-Reference-Cited by-同舟云学术

Advances in Targeting HER3 as an Anticancer Therapy

Published:2012-11-07 Issue: Volume:2012 Page:1-9
ISSN:2090-2107
Container-title:Chemotherapy Research and Practice
language:en
Short-container-title:Chemotherapy Research and Practice

Author:

Jiang Ning¹²,Saba Nabil F.²,Chen Zhuo Georgia²

Affiliation:

1. State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangdong, Guangzhou 510060, China

2. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, NE, Atlanta, GA 30322, USA

Abstract

HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications.

Publisher

Hindawi Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Oncology

Link

http://downloads.hindawi.com/archive/2012/817304.pdf

Reference96 articles.

1. NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein

3. ERBB receptors and cancer: the complexity of targeted inhibitors

4. Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

5. Specificity within the EGF family/ErbB receptor family signaling network

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long road towards effective HER3 targeting in breast cancer;Cancer Treatment Reviews;2024-09

2. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

3. Comprehensive Assessment of OCR Tools for Gene Name Recognition in Biological Pathway Figures;2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM);2022-12-06

4. Beyond HER2: Targeting the ErbB receptor family in breast cancer;Cancer Treatment Reviews;2022-09

5. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?;Journal of Experimental & Clinical Cancer Research;2022-08-15